Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts

Published:2013-11-18 Issue:10 Volume:134 Page:2322-2329
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Ingels Alexandre¹²,Zhao Hongjuan¹,Thong Alan E.¹,Saar Matthias¹³,Valta Maija P.¹⁴,Nolley Rosalie¹,Santos Jennifer¹,Peehl Donna M.¹

Affiliation:

1. Department of Urology; Stanford University School of Medicine; Stanford CA

2. Department of Urology; Centre Hospitalier Universitaire du Kremlin-Bicêtre; Kremlin-Bicêtre France

3. Department of Urology and Pediatric Urology; University of Saarland; Homburg/Saar Germany

4. Division of Medicine; Turku University Hospital and University of Turku; Turku Finland

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference34 articles.

1. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy;Pantuck;Cancer,2007

2. Activation of the mTOR signaling pathway in renal clear cell carcinoma;Robb;J Urol,2007

3. Differentiating mTOR inhibitors in renal cell carcinoma;Pal;Cancer Treat Rev,2013

4. mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice;Barthelemy;Crit Rev Oncol Hematol,2013

5. mTOR inhibitors in advanced renal cell carcinoma;Voss;Hematol Oncol Clin North Am,2011

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy;Cancers;2022-11-10

2. Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening;Cancers;2022-03-19

3. Preclinical evaluation of the dual mTORC1/2 inhibitor sapanisertib in combination with cisplatin in nasopharyngeal carcinoma;European Journal of Pharmacology;2022-01

4. Inhibition of the HIF-1 Survival Pathway as a Strategy to Augment Photodynamic Therapy Efficacy;Methods in Molecular Biology;2022

5. A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies;Targeted Oncology;2021-11-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3